<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Gynecology</journal-id><journal-title-group><journal-title xml:lang="en">Gynecology</journal-title><trans-title-group xml:lang="ru"><trans-title>Гинекология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2079-5696</issn><issn publication-format="electronic">2079-5831</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">104395</article-id><article-id pub-id-type="doi">10.26442/20795696.2022.2.201438</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL ARTICLE</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНАЯ СТАТЬЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Evaluation of results of combined treatment in patients with disseminated ovarian cancer</article-title><trans-title-group xml:lang="ru"><trans-title>Оценка результатов комбинированного лечения пациентов с диссеминированным раком яичников</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0179-7635</contrib-id><name-alternatives><name xml:lang="en"><surname>Iurova</surname><given-names>Mariia V.</given-names></name><name xml:lang="ru"><surname>Юрова</surname><given-names>Мария Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Graduate Student</p></bio><bio xml:lang="ru"><p>аспирант каф. акушерства, гинекологии, перинатологии и репродуктивного здоровья; специалист</p></bio><email>m_yurova@oparina4.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5011-9152</contrib-id><name-alternatives><name xml:lang="en"><surname>Khabas</surname><given-names>Grigory N.</given-names></name><name xml:lang="ru"><surname>Хабас</surname><given-names>Григорий Николаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>канд. мед. наук, рук. отд-ния инновационной онкологии и гинекологии</p></bio><email>g_khabas@oparina4.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1313-7079</contrib-id><name-alternatives><name xml:lang="en"><surname>Pavlovich</surname><given-names>Stanislav V.</given-names></name><name xml:lang="ru"><surname>Павлович</surname><given-names>Станислав Владиславович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>канд. мед. наук, зав. учебной частью каф. акушерства, гинекологии, перинатологии и репродуктивного здоровья; ученый секретарь</p></bio><email>s_pavlovich@oparina4.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Sechenov First Moscow State Medical University (Sechenov University)</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. акад. В.И. Кулакова» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-04-15" publication-format="electronic"><day>15</day><month>04</month><year>2022</year></pub-date><volume>24</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>132</fpage><lpage>139</lpage><history><date date-type="received" iso-8601-date="2022-03-03"><day>03</day><month>03</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-03-28"><day>28</day><month>03</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://gynecology.orscience.ru/2079-5831/article/view/104395">https://gynecology.orscience.ru/2079-5831/article/view/104395</self-uri><abstract xml:lang="en"><p><bold>Background.</bold> According to the modern concept of surgical treatment of ovarian cancer (OC) it is necessary to perform cytoreductive surgery (CRS) without residual tumor in order to achieve more favorable oncological prognoses. However, the possibilities of achieving it with a disseminated process (stages III–IV) are limited, and therefore, for some patients, neoadjuvant chemotherapy (NACT) is the optimal initial treatment.</p> <p><bold>Aim. </bold>To compare the duration of progression-free survival (PFS) of patients with advanced OC after treatment, as well as to assess the value of the prognostic nutritional index (PNI) in predicting this outcome.</p> <p><bold>Materials and methods. </bold>We conducted a retrospective cohort study of 78 patients with stages III–IV OC, who received combined treatment between January 2016 and March 2020 (54 patients after primary CRS (PCRS)+platinum-based chemotherapy (CT), 24 patients after NACT+interval CRS (ICRS)+postoperative CT. The predictive value of the PNI was calculated.</p> <p><bold>Results. </bold>The complete PCRS is associated with increased PFS: after complete PCRS – 32±11.21 months (95% confidence interval – CI 10.09–53.97); after optimal PCRS – 22±3.46 months (95% CI 15.21–28.79); after suboptimal PCRS – 14±7 months (95% CI 0.28–27.72). Performing a complete ICRS is associated with decreased PFS compared to PCRS, even if the complete CRS is achieved: after complete ICRS – 14±3.34 months (95% CI 7.46–20.54); after optimal ICRS – 17±2.16 months (95% CI 12.77–21.23); after suboptimal ICRS – 7 months. PNI≥27.86 correlates with an increased probability of complete PCRS in patients with advanced PCR (AUC 94.3, sensitivity – 80%, specificity – 91.7%; <italic>p</italic>&lt;0.001).</p> <p><bold>Conclusion. </bold>Achieving complete PCRS in patients with disseminated OC leads to an improvement in the oncological outcome. The prognostic value of pre-treatment calculation of PNI has been revealed: an increased PNI is associated with more favorable perioperative outcomes. Objective criteria should be developed for a strictly reasoned refusal to carry out the first stage of surgical treatment due to the obviously less favorable prognosis of the tactics of "NACT+ICRS+CT".</p></abstract><trans-abstract xml:lang="ru"><p><bold>Актуальность. </bold>Согласно современной концепции хирургического лечения рака яичников (РЯ), необходимо выполнить циторедуктивную операцию (ЦРО) без остаточной опухоли, однако возможности достижения полной ЦРО при диссеминированном процессе (III–IV стадии) ограничены, в связи с чем некоторым пациентам на I этапе лечения выполняют индукционную неоадъювантную химиотерапию (НАХТ).</p> <p><bold>Цель. </bold>Сравнить длительность выживаемости без прогрессирования (ВБП) у пациентов с распространенным РЯ после лечения, а также оценить значение прогностического нутритивного статуса в предикции данного исхода.</p> <p><bold>Материалы и методы. </bold>В исследование были включены 78 пациентов с III–IV стадиями РЯ по классификации Международной федерации акушеров и гинекологов, которые получали комбинированное лечение в НМИЦ «АГП им. акад. В.И. Кулакова» с января 2016 по март 2020 г. Первичную ЦРО (ПЦРО)+платиносодержащую химиотерапию (ХТ) прошли 54 пациента; НАХТ+интервальную ЦРО (ИЦРО)+послеоперационную ХТ провели 24 женщинам. Проанализирована предикторная значимость прогностического нутритивного индекса (ПНИ).</p> <p><bold>Результаты. </bold>Достижение полной ПЦРО сопровождается удлинением ВБП: после полной ПЦРО – 32±11,21 мес (95% доверительный интервал – ДИ 10,09–53,97); после оптимальной ПЦРО – 22±3,46 мес (95% ДИ 15,21–28,79); после неоптимальной ПЦРО – 14±7 мес (95% ДИ 0,28–27,72). Выполнение полной ИЦРО сопровождается статистически значимым сокращением ВБП по сравнению с ПЦРО даже при условии выполнения операции без остаточной опухоли: после полной ИЦРО – 14±3,34 мес (95% ДИ 7,46–20,54); после оптимальной ИЦРО – 17±2,16 мес (95% ДИ 12,77–21,23); после неоптимальной ИЦРО – 7 мес. ПНИ≥27,86 сопровождается повышением вероятности выполнения ПЦРО без остаточной опухоли у пациентов с распространенным РЯ (AUC 94,3, чувствительность – 80%, специфичность – 91,7%; <italic>р</italic>&lt;0,001).</p> <p><bold>Заключение. </bold>Показана целесообразность стремления выполнять полную ПЦРО пациентам с распространенным РЯ. Выявлена прогностическая ценность учета ПНИ при планировании ПЦРО: повышение ПНИ сопряжено с более благоприятными периоперационными исходами. Следует разрабатывать объективные критерии для строго аргументированного отказа от проведения I этапом хирургического лечения в связи с заведомо менее благоприятным прогнозом тактики «НАХТ+ИЦРО+ХТ».</p></trans-abstract><kwd-group xml:lang="en"><kwd>albumin</kwd><kwd>neoadjuvant chemotherapy</kwd><kwd>prognostic nutritional index</kwd><kwd>complete cytoreduction</kwd><kwd>ovarian cancer</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>альбумин</kwd><kwd>неоадъювантная химиотерапия</kwd><kwd>нутритивный статус</kwd><kwd>полная циторедукция</kwd><kwd>рак яичников</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Состояние онкологической помощи населению России в 2019 году. Под ред. Каприна А.Д., Старинского В.В., Шахзадовой А.О. М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020 [Sostoianie onkologicheskoi pomoshchi naseleniiu Rossii v 2019 godu. Pod red. Kaprina AD, Starinskogo VV, Shakhzadovoi AO. Moscow: MNIOI im. PA Gertsena − filial FGBU “NMITs radiologii” Minzdrava Rossii, 2020 (in Russian)].</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Назаренко Т.А., Ашрафян Л.А., Джанашвили Л.Г., Мартиросян Я.О. Сохранение репродуктивного материала у онкологических больных как медико-социальная и организационная проблема. Онкология. Журнал им. П.А. Герцена. 2020;9(1):60-5 [Nazarenko TA, Ashrafian LA, Dzhanashvili LG, Martirosyan YO. Retention of reproductive material in cancer patients as a sociomedical and organizational problem. P.A. Herzen Journal of Oncology. 2020;9(1):60-5 (in Russian)]. DOI:10.17116/onkolog2020901160</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Tomao F, Di Pinto A, Sassu CM, et al. Fertility preservation in ovarian tumours. Ecancermedicalscience. 2018;12:885. DOI:10.3332/ecancer.2018.885</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Ashraf MA, Dasari P. Outcome of fertility-preserving surgery for ovarian malignancy in young women. Case Rep. 2018;1(1):51-4.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30. DOI:10.3322/caac.21590</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Состояние онкологической помощи населению России В 2020 году. Под ред. Каприна А.Д., Старинского В.В., Шахзадовой А.О. М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2021 [Sostoianie onkologicheskoi pomoshchi naseleniiu Rossii V 2020 godu. Pod red. Kaprina AD, Starinskogo VV, Shakhzadovoi AO. Moscow: MNIOI im. PA Gertsena − filial FGBU “NMITs radiologii” Minzdrava Rossii, 2021 (in Russian)].</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Colombo N, Sessa C, du Bois A, et al. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol. 2019;30(5):672-705. DOI:10.1093/annonc/mdz062</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Querleu D, Planchamp F, Chiva L, et al. European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery. Int J Gynecol Cancer. 2017;27(7):1534-42. DOI:10.1097/IGC.0000000000001041</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Armstrong DK, Alvarez RD, Bakkum-Gamez JN. NCCN Clinical Practice Guidelines in Oncology. Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. 2021;3:1-254. Available at: https://www.lissod.com.ua/doctor/files/ovarian-Рак%20яичников.pdf Accssed: 15.08.2021.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Koirala P, Moon AS, Chuang L. Clinical Utility of Preoperative Assessment in Ovarian Cancer Cytoreduction. Diagnostics (Basel). 2020;10(8):568. DOI:10.3390/diagnostics10080568</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Froyman W, Landolfo C, De Cock B, et al. Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort study. Lancet Oncol. 2019;20(3):448-58. DOI:10.1016/S1470-2045(18)30837-4</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Sugarbaker PH. Comprehensive management of peritoneal surface malignancy using cytoreductive surgery and perioperative intraperitoneal chemotherapy: the Washington Cancer Institute approach. Expert Opin Pharmacother. 2009;10(12):1965-77. DOI:10.1517/14656560903044974</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Sugarbaker PH. Preoperative Assessment of Cancer Patients with Peritoneal Metastases for Complete Cytoreduction. Indian J Surg Oncol. 2016;7:295-302. DOI:10.1007/s13193-016-0518-0</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Sugarbaker PH, Van der Speeten K, Stuart OA. Pharmacologic rationale for treatments of peritoneal surface malignancy from colorectal cancer. World J Gastrointest Oncol. 2010;2(1):19-30. DOI:10.4251/wjgo.v2.i1.19</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009;115(6):1234-44. DOI:10.1002/cncr.24149</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Chi DS, Eisenhauer EL, Zivanovic O, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114(1):26-31. DOI:10.1016/j.ygyno.2009.03.018</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Böhm S, Faruqi A, Said I, et al. Chemotherapy Response Score : Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma. J Clin Oncol. 2015;33(22):2457-63. DOI:10.1200/JCO.2014.60.5212</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Cohen PA, Powell A, Böhm S, et al. Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma : A systematic review and meta-analysis of individual patient data. Gynecol Oncol. 2019;154(2):441-8. DOI:10.1016/j.ygyno.2019.04.679</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Meyer LA, Cronin AM, Sun CC, et al. Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer. J Clin Oncol. 2016;34(32):3854-63. DOI:10.1200/JCO.2016.68.1239</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Onda T, Satoh T, Ogawa G, et al. Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial. Eur J Cancer. 2020;130:114-25. DOI:10.1016/j.ejca.2020.02.020</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Fagotti A, Ferrandina MG, Vizzielli G, et al. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION–NCT01461850). Int J Gynecol Cancer. 2020;30(11):1657-64. DOI:10.1136/ijgc-2020-001640</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Nougaret S, Addley HC, Colombo PE, et al. Ovarian Carcinomatosis: how the radiologist can help plan the surgical approach. Radiographics. 2012;32(6):1775-800. DOI:10.1148/rg.326125511</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Komura N, Mabuchi S, Yokoi E, et al. Prognostic significance of the pretreatment prognostic nutritional index in patients with epithelial ovarian cancer. Oncotarget. 2019;10(38):3605-13. DOI:10.18632/oncotarget.26914</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Feng Z, Wen H, Ju X, et al. The preoperative prognostic nutritional index is a predictive and prognostic factor of high-grade serous ovarian cancer. BMC Cancer. 2018;18(1):883. DOI:10.1186/s12885-018-4732-8</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Demir A, Alan O, Koca S, Surmeli H. The Relationship Between the Prognostic Nutritional Index and Overall Survival in Elderly Patients with Epithelial Ovarian Cancer. EJMI. 2020;4(2):269-73. DOI:10.14744/ejmi.2020.30288</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Pasha K, Ramesh Kumar B, Macherla R, et al. Biochemical Markers of Ascitic Fluid to Differentiate Ovarian Cancer from Liver Cirrhosis Patients. J Clin Diagn Res. 2020;14(6):BC01-4. DOI:10.7860/JCDR/2020/44135.13765</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Zhang W, Ye B, Liang W, Ren Y. Preoperative prognostic nutritional index is a powerful predictor of prognosis in patients with stage III ovarian cancer. Sci Rep. 2017;7(1):9548. DOI:10.1038/s41598-017-10328-8</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Miao Y, Li S, Yan Q, et al. Prognostic Significance of Preoperative Prognostic Nutritional Index in Epithelial Ovarian Cancer Patients Treated with Platinum-Based Chemotherapy. Oncol Res Treat. 2016;39(11):712-9. DOI:10.1159/000452263</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Dai D, Balega J, Sundar S, et al. Serum Albumin as a Predictor of Survival after Interval Debulking Surgery for Advanced Ovarian Cancer (AOC): A Retrospective Study. J Invest Surg. 2022;35(2):426-31. DOI:10.1080/08941939.2020.1827314</mixed-citation></ref></ref-list></back></article>
